International Journal of Cancer Management

Published by: Kowsar

Evaluation of the Gene Expression of the Cytoprotective Proteins in Response to Daunorubicin in U937 Cells

Saeed Mohammadi 1 , Mahdi Zahedpanah 2 , * , Seyed Hamidollah Ghaffari 1 , Mojgan Shaiegan 3 , Mohsen Nikbakht 1 , Mahin Nikugoftar 3 , Babak Rahmani 4 and Dariush Hamedi Asl 4
Authors Information
1 Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
3 Blood Transfusion Research center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
4 Department of Biochemistry and Genetics, Qazvin University of Medical Sciences, Qazvin, Iran
Article information
  • International Journal of Cancer Management: April 2018, 11 (4); e10044
  • Published Online: April 28, 2018
  • Article Type: Research Article
  • Received: December 14, 2016
  • Revised: March 19, 2017
  • Accepted: March 4, 2018
  • DOI: 10.5812/ijcm.10044

To Cite: Mohammadi S, Zahedpanah M, Ghaffari S H, Shaiegan M, Nikbakht M, et al. Evaluation of the Gene Expression of the Cytoprotective Proteins in Response to Daunorubicin in U937 Cells, Int J Cancer Manag. 2018 ; 11(4):e10044. doi: 10.5812/ijcm.10044.

Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516. doi: 10.1080/01926230701320337. [PubMed: 17562483].
  • 2. Greer JP, Arber DA, Glader B, List AF, Robert T, Means J, et al. Wintrobe's Clinical Hematology. 13 ed. Philadelphia: Lippincott williams & wilkins; 2014.
  • 3. Laurent G, Jaffrezou JP. Signaling pathways activated by daunorubicin. Blood. 2001;98(4):913-24. [PubMed: 11493433].
  • 4. Dartsch DC, Schaefer A, Boldt S, Kolch W, Marquardt H. Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis. Apoptosis. 2002;7(6):537-48. [PubMed: 12370496].
  • 5. Sugimoto K, Tamayose K, Sasaki M, Hayashi K, Oshimi K. Low-dose doxorubicin-induced necrosis in Jurkat cells and its acceleration and conversion to apoptosis by antioxidants. Br J Haematol. 2002;118(1):229-38. [PubMed: 12100152].
  • 6. Bailly JD, Muller C, Jaffrezou JP, Demur C, Gassar G, Bordier C, et al. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia. 1995;9(5):799-807. [PubMed: 7769842].
  • 7. Quillet-Mary A, Mansat V, Duchayne E, Come MG, Allouche M, Bailly JD, et al. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia. 1996;10(3):417-25. [PubMed: 8642856].
  • 8. Bertho AL, Santiago MA, Coutinho SG. Flow cytometry in the study of cell death. Mem Inst Oswaldo Cruz. 2000;95(3):429-33. [PubMed: 10800202].
  • 9. Mansat-de Mas V, Bezombes C, Quillet-Mary A, Bettaieb A, D'Orgeix A D, Laurent G, et al. Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol Pharmacol. 1999;56(5):867-74. [PubMed: 10531389].
  • 10. Troyano A, Sancho P, Fernandez C, de Blas E, Bernardi P, Aller P. The selection between apoptosis and necrosis is differentially regulated in hydrogen peroxide-treated and glutathione-depleted human promonocytic cells. Cell Death Differ. 2003;10(8):889-98. doi: 10.1038/sj.cdd.4401249. [PubMed: 12867996].
  • 11. Lautier D, Bailly JD, Demur C, Herbert JM, Bousquet C, Laurent G. Altered intracellular distribution of daunorubicin in immature acute myeloid leukemia cells. Int J Cancer. 1997;71(2):292-9. [PubMed: 9139856].
  • 12. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005;106(4):1232-9. doi: 10.1182/blood-2004-11-4422. [PubMed: 15845900].
  • 13. Boyerinas B, Zafrir M, Yesilkanal AE, Price TT, Hyjek EM, Sipkins DA. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood. 2013;121(24):4821-31. doi: 10.1182/blood-2012-12-475483. [PubMed: 23589674].
  • 14. Iwata M, Awaya N, Graf L, Kahl C, Torok-Storb B. Human marrow stromal cells activate monocytes to secrete osteopontin, which down-regulates Notch1 gene expression in CD34+ cells. Blood. 2004;103(12):4496-502. doi: 10.1182/blood-2004-01-0256. [PubMed: 14996707].
  • 15. Lin YH, Huang CJ, Chao JR, Chen ST, Lee SF, Yen JJ, et al. Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Mol Cell Biol. 2000;20(8):2734-42. [PubMed: 10733576].
  • 16. Lee CY, Tien HF, Hou HA, Chou WC, Lin LI. Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia. Br J Haematol. 2008;141(5):736-9. doi: 10.1111/j.1365-2141.2008.07082.x. [PubMed: 18397342].
  • 17. Caers J, Gunthert U, De Raeve H, Van Valckenborgh E, Menu E, Van Riet I, et al. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol. 2006;132(4):469-77. doi: 10.1111/j.1365-2141.2005.05886.x. [PubMed: 16412019].
  • 18. Delany AM. Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma. Cancer Biol Ther. 2010;10(1):65-7. [PubMed: 20657168].
  • 19. Mi Z, Guo H, Kuo PC. Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer. BMC Res Notes. 2009;2:119. doi: 10.1186/1756-0500-2-119. [PubMed: 19570203].
  • 20. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005;446(5):475-82. doi: 10.1007/s00428-005-1264-9. [PubMed: 15856292].
  • 21. Gilliland DG. The Molecular Basis of Leukemia. Hematology. 2004;2004(1):80-97. doi: 10.1182/asheducation-2004.1.80.
  • 22. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, et al. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol. 2001;152(1):87-96. [PubMed: 11149923].
  • 23. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol. 2004;24(7):2890-904. [PubMed: 15024077].
  • 24. Das KC, White CW. Activation of NF-κB by Antineoplastic Agents Role of Protein Kinase c. J Biol Chem. 1997;272(23):14914-20. doi: 10.1074/jbc.272.23.14914.
  • 25. Wang Z, Huang Y, Zhang J. Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy. Cell Mol Biol Lett. 2014;19(2):233-42. doi: 10.2478/s11658-014-0191-7. [PubMed: 24728800].
  • 26. Plo I, Bettaieb A, Payrastre B, Mansat-De Mas V, Bordier C, Rousse A, et al. The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines. FEBS Lett. 1999;452(3):150-4. [PubMed: 10386580].
  • 27. Sugatani T, Alvarez U, Hruska KA. PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility. J Biol Chem. 2003;278(7):5001-8. doi: 10.1074/jbc.M209299200. [PubMed: 12460992].
  • 28. Liu TC, Lin PM, Chang JG, Lee JP, Chen TP, Lin SF. Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol. 2000;63(4):170-5. [PubMed: 10706759].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments